Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

BACKGROUND: To assess the safety profile, pharmacokinetics, pharmacodynamics and preliminary antitumour activity of fixed-dose SHR-1210, a novel anti-PD-1 antibody, in advanced solid tumours. METHODS: A total of 36 patients with advanced solid tumours received intravenous SHR-1210 at 60 mg, 200 mg a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Mo, Hongnan, Huang, Jing, Xu, Jiachen, Chen, Xuelian, Wu, Dawei, Qu, Dong, Wang, Xi, Lan, Bo, Wang, Xingyuan, Xu, Jianping, Zhang, Honggang, Chi, Yihebali, Yang, Qing, Xu, Binghe
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6162236/
https://ncbi.nlm.nih.gov/pubmed/29755117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0100-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars